Track XFOR and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$158.38M
Enterprise Value-$17.33M
Revenue (TTM)$35.11M
Net Income (TTM)-$79.20M
Free Cash Flow (TTM)-$85.62M
Financial Health
Cash$253.00M
Net Debt-$175.71M
Debt Ratio0.27
Debt to Equity0.41
Interest Coverage-10.84
Valuation (TTM)
Price to Sales4.51
Price to Earnings-2
EV to EBITDA0.2
Price to Book0.85
Price to Free Cash Flow-1.85
Margins (TTM)
Gross Profit Margin82.18%
EBITDA Margin-243.80%
Operating Income Margin-247.44%
Net Income Margin-225.55%
Free Cash Flow Margin-243.84%
Returns (5Y Avg)
Return on Invested Capital-63.01%
Return on Assets-49.74%
Return on Equity-134.81%
Return on Total Capital-63.01%
Return on Capital Employed-58.01%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue63.56%
Diluted EPS147.39%
Total Debt17.87%
Capital Expenditures17.11%
Free Cash Flow-8.66%
CAGR (3Y)
Revenue1000.00%
Diluted EPS204.49%
Total Debt30.45%
Capital Expenditures207.68%
Free Cash Flow-6.67%
CAGR (1Y)
Revenue1000.00%
Diluted EPS481.99%
Total Debt0.79%
Capital Expenditures-59.05%
Free Cash Flow1000.00%
$3.69+$0.01|+0.27%
52W High$4.83
52W Low$1.35
50D SMA$4.02
200D SMA$3.84
Volume426.06K
X4 Pharmaceuticals Inc
61 North Beacon Street, Boston, MA, United States, 02134
IPO
2017
Employees
45
Industry
Biotechnology
Sector
Healthcare
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20250+1
1
Q2 20250+1
1
2-quarter cumulative
0 sells2 buys
Analyst Ratings
2 analysts covering
Buy100%recommend buy
Buy
2
Hold
0
Sell
0